Evidence map›Paper›PMID 42294112›Full record

ArticleBlood neoplasia2026

Validation of ELN 2024 genetic classification in patients with AML treated with HMA-based regimens: PETHEMA registry study.

Eva Barragán, José Vicente Gil, Rosa Ayala, Carmen Chillón, Elena Soria, Cristina Bilbao, María José Larráyoz, Esther Prados de la Torre, Antonio Solana, David Martínez-Cuadrón and 51 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood neoplasia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

61 authors.

Eva BarragánMolecular Biology Unit, Hospital Universitari i Politècnic La Fe-Instituto Investigación Sanitaria La Fe, Valencia, Spain.
José Vicente GilMolecular Biology Unit, Hospital Universitari i Politècnic La Fe-Instituto Investigación Sanitaria La Fe, Valencia, Spain.
Rosa AyalaHematology Department, Hospital Universitario 12 de Octubre, CNIO, Complutense University, CIBERONC, Madrid, Spain.
Carmen ChillónHematology Department, Hospital Universitario de Salamanca, Instituto de Biología Molecular y Celular del Cáncer and CIBERONC, Salamanca, Spain.
Elena SoriaHematology Department, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina, Universidad de Sevilla, Seville, Spain.
Cristina BilbaoHematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
María José LarráyozCIMA LAB Diagnostics CUN Pamplona Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
Esther Prados de la TorreIMIBIC, Hematology, Hospital Universitario Reina Sofía, UCO, Córdoba, Spain.
Antonio SolanaHematology Department, Hospital Universitari i Politécnic La Fe-Instituto Investigación Sanitaria La Fe, Valencia, Spain.
David Martínez-CuadrónCIBERONC Instituto de Salud Carlos III, Madrid, Spain.
Rebeca Rodríguez-VeigaHematology Department, Hospital Universitari i Politécnic La Fe-Instituto Investigación Sanitaria La Fe, Valencia, Spain.
Eduardo Rodríguez-ArbolíHematology Department, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina, Universidad de Sevilla, Seville, Spain.
Mar TormoHematology Department, Hospital Clínico Universitario- Instituto de Investigación Sanitaria H Clínico Valencia, Valencia, Spain.
Pilar MartínezHematology Department, Hospital Universitario 12 de Octubre, CNIO, Complutense University, CIBERONC, Madrid, Spain.
Esperanza LavillaHematology Department, Hospital Universitario Lucus Augusti, Lugo, Spain.
María Carmen García-GarayHematology Department, Hospital Universitario Virgen de la Arrixaca, Murcia, Spain.
Olga ArceHematology Department, Basurtuko Ospitalea, Bilbao, Spain.
Juan BerguaHematology Department, Hospital San Pedro de Alcántara, Cáceres, Spain.
Josefina SerranoIMIBIC, Hematology, Hospital Universitario Reina Sofía, UCO, Córdoba, Spain.
Carmen BotellaHematology Department, Hospital General Universitario de Alicante, Alicante, Spain.
Carolina LacalzadaHematology Department, Hospital Universitario de Canarias, La Laguna Tenerife, Spain.
Agatha Almela-GallegoHematology Department, Hospital Universitario de León, León, Spain.
José Luis Lopez-LorenzoHematology Department, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
Marta ValeroHematology Department, Hospital Arnau de Vilanova, Valencia, Spain.
Francisco IbañezHematology Department, Hospital General Universitario de Valencia, Valencia, Spain.
María Ángeles FoncillasHematology Department, Hospital Infanta Leonor, Madrid, Spain.
Carlos Rodriguez-MedinaHematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
Maite OlaveHematology Department, Hospital Clínico U. Lozano Blesa, Zaragoza, Spain.
Karol Giovanna Gómez-CorrechaHematology Department, Hospital Juan Ramón Jimenez, Huelva, Spain.
María Teresa CalderónHematology Department, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain.
Teresa BernalHematology Department, Hospital Universitario Central de Asturias, Instituto Universitario de Oncología del Principado de Asturias, Oviedo, Spain.
Jorge LabradorHematology Department, Hospital Universitario de Burgos, Burgos, Spain.
Ana OlivaHematology Department, Hospital Universitario Nuestra Señora de Candelaria, Tenerife, Spain.
María Dolores MadrigalHematology Department, Hospital Universitario Virgen Macarena, Sevilla, Spain.
Lourdes HermosínHematology Department, Hospital de Jerez de La Frontera, Cadiz, Spain.
Lourdes AmadorHematology Department, Hospital de Montecelo, Pontevedra, Spain.
Daniel García-BelmonteHematology Department, Hospital Sanitas La Zarzuela, Madrid, Spain.
Pilar HerreraHematology Department, Hospital Ramón y Cajal, Madrid, Spain.
Susana VivesHematology Department, Hospital Germans Trias i Pujol, Badalona, Spain.
Manuel Perez-EncinasHematology Department, Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain.
Lorenzo AlgarraHematology Department, Hospital General Universitario de Albacete, Albacete, Spain.
Soledad CasadoHematology Department, Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain.
Carmen Martínez-ChamorroHematology Department, Hospital Universitario Quirón Salud Madrid, Madrid, Spain.
Marta PoloHematology Department, Hospital Clínico San Carlos, Madrid, Spain.
Amaia BalerdiHematology Department, Hospital Universitario de Cruces, Barakaldo, Spain.
Alicia RoldánHematology Department, Hospital Infanta Sofía San Sebastián de los Reyes, Madrid, Spain.
Carmen CoutoHematology Department, Hospital Virgen de Valme, Seville, Spain.
María PereiroHematology Department, Complejo Hospitalario de Ourense, Ourense, Spain.
Raúl VanegasHematology Department, Hospital de Ciudad Real, Ciudad Real, Spain.
Marta LlopMolecular Biology Unit, Hospital Universitari i Politècnic La Fe-Instituto Investigación Sanitaria La Fe, Valencia, Spain.
Claudia SargasMolecular Biology Unit, Hospital Universitari i Politècnic La Fe-Instituto Investigación Sanitaria La Fe, Valencia, Spain.
Antonia CionfriniHematology Department, Hospital Universitari i Politécnic La Fe-Instituto Investigación Sanitaria La Fe, Valencia, Spain.
Yolanda MendizábalHematology Department, Hospital Universitari i Politécnic La Fe-Instituto Investigación Sanitaria La Fe, Valencia, Spain.
Joaquín SánchezIMIBIC, Hematology, Hospital Universitario Reina Sofía, UCO, Córdoba, Spain.
María José CalasanzCIMA LAB Diagnostics CUN Pamplona Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
María Teresa Gómez-CasaresHematology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.
José Antonio Pérez-SimónHematology Department, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina, Universidad de Sevilla, Seville, Spain.
Ramón García-SanzHematology Department, Hospital Universitario de Salamanca, Instituto de Biología Molecular y Celular del Cáncer and CIBERONC, Salamanca, Spain.
Joaquín Martínez-LópezHematology Department, Hospital Universitario 12 de Octubre, CNIO, Complutense University, CIBERONC, Madrid, Spain.
Pau MontesinosCIBERONC Instituto de Salud Carlos III, Madrid, Spain.
PETHEMA group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The 2024 European LeukemiaNet (ELN 2024) genetic risk classification was proposed to assess prognosis in patients with acute myeloid leukemia (AML) receiving less-intensive hypomethylating agent (HMA)-based regimens. However, its applicability to real-world patients remains unclear. We retrospectively analyzed 669 adult patients with AML from the PETHEMA registry treated in routine practice with HMA monotherapy (n = 414) or HMA-venetoclax (VEN) (n = 255). Molecular profiling was performed centrally among the Programa Español de Tratamientos en Hematología (PETHEMA) laboratory network. Median age was 75 years, and 48% had secondary AML (s-AML). Across the full cohort, ELN 2024 stratified patients into prognostic groups across both regimens, but overall survival (OS) was consistently shorter with HMA monotherapy than with HMA-VEN (median OS, 6.5 vs 11.2 months). Favorable risk patients treated with HMA-VEN achieved a median OS exceeding 18.4 months, whereas adverse risk patients had an OS of 7.7 months. ELN 2024 provides meaningful stratification in nonintensive AML, especially with HMA-VEN. However, prognostic accuracy is limited in HMA monotherapy and s-AML, particularly those arising from a myeloid neoplasm (sM-AML). Incorporating cytogenetic risk and sM-AML as adverse risk improved discrimination (area under the curve at 24 months, 0.71 vs 0.76). Refinement incorporating clinical history, cytogenetics, emerging mutations, and treatment response is needed to improve risk prediction in real-world populations.

Identifiers

PMID42294112
PMCPMC13254578

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.